Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2016055797) VALPROIC ACID FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2016/055797 International Application No.: PCT/GB2015/052950
Publication Date: 14.04.2016 International Filing Date: 08.10.2015
IPC:
A61K 31/19 (2006.01) ,A61K 31/4365 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/616 (2006.01) ,A61P 7/02 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
4365
the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
60
Salicylic acid; Derivatives thereof
612
having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
616
by carboxylic acids, e.g. acetylsalicylic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7
Drugs for disorders of the blood or the extracellular fluid
02
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Applicants:
CERENO SCIENTIFIC AB [SE/SE]; Erik Dahlbergsgatan 11A SE 411 26 Göteborg, SE
Inventors:
JERN, Sverker; SE
SÄLJÖ, Jonas Faijerson; SE
BERGH, Niklas; SE
Agent:
MCNEENEY, Stephen Phillip; GB
Priority Data:
1417828.908.10.2014GB
Title (EN) VALPROIC ACID FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION
(FR) COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT OU LA PRÉVENTION D'AFFECTIONS PATHOLOGIQUES ASSOCIÉES À L'EXCÈS DE DÉPÔT DE FIBRINE ET/OU À LA FORMATION DE THROMBUS
Abstract:
(EN) There is herein provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation, wherein said treatment comprises treating a patient with valproic acid, or a pharmaceutically acceptable salt thereof, in a specific manner, and formulations for use or designed for use in such treatments.
(FR) La présente invention concerne l'acide valproïque, ou un sel pharmaceutiquement acceptable de celui-ci, pour son utilisation dans le traitement ou la prévention d'une condition pathologique associée à un excès de dépôt de fibrine et/ou à la formation de thrombus, ledit traitement comprenant le traitement d'un patient avec de l'acide valproïque, ou un sel pharmaceutiquement acceptable de celui-ci, d'une manière spécifique, et des formulations destinées à être utilisées ou conçues pour être utilisées dans de tels traitements.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU2015329795CA2964041SG11201702058XKR1020170063857MYPI 2017701203IL251142
CN107205975JP2017532376IN201717015504MX2017004558ID2018/02654BR112017007144
US20180177751RU2017114933